secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001654954-24-015161
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics appoints Thomas A. McGauley as Interim CFO, effective Dec 2, 2024
--------------------------------------------------------------------------------

- Thomas A. McGauley appointed Interim CFO and principal financial/accounting officer, replacing Lawrence R. Hoffman.
- McGauley provides services through Danforth Advisors at $410 per hour with up to 4% annual increase.
- McGauley has 25+ years financial experience, including interim CFO at Galectin Therapeutics and manager at PwC.
- He holds a CPA and B.S.B.A in Accounting from Stonehill College; no familial relationships with officers or directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424015161/0001654954-24-015161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424015161/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-015161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer